{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:08Z","timestamp":1786119668272,"version":"build-2736575974"},"reference-count":171,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1097\/med.0b013e328089f0ea","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T02:02:06Z","timestamp":1294970526000},"page":"132-140","source":"Crossref","is-referenced-by-count":7,"title":["Metformin and polycystic ovary syndrome"],"prefix":"10.1097","volume":"14","author":[{"given":"Tessa G","family":"Lebinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-7-20211004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.","volume":"81","year":"2004","journal-title":"Fertil Steril"},{"key":"R3-7-20211004","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1210\/jc.2005-2153","article-title":"Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-7-20211004","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1210\/jc.2005-2501","article-title":"Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria","volume":"91","author":"Franks","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-7-20211004","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-7-20211004","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2265.2006.02611.x","article-title":"Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma","volume":"65","author":"Fulghesu","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R7-7-20211004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/humupd\/dmg044","article-title":"Ultrasound assessment of the polycystic ovary: international consensus definitions","volume":"9","author":"Balen","year":"2003","journal-title":"Hum Reprod Update"},{"key":"R8-7-20211004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2265.1980.tb02132.x","article-title":"The polycystic ovary syndrome","volume":"12","author":"Yen","year":"1980","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R9-7-20211004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1210\/er.16.3.322","article-title":"Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion","volume":"16","author":"Ehrmann","year":"1995","journal-title":"Endocr Rev"},{"key":"R10-7-20211004","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr Rev"},{"key":"R11-7-20211004","first-page":"613","article-title":"Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome","volume":"84","author":"Poretsky","year":"1994","journal-title":"Obstet Gynecol"},{"key":"R12-7-20211004","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/edrv.20.4.0374","article-title":"The insulin-related ovarian regulatory system in health and disease","volume":"20","author":"Poretsky","year":"1999","journal-title":"Endocr Rev"},{"key":"R13-7-20211004","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0015-0282(16)47064-0","article-title":"Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome","volume":"39","author":"Lobo","year":"1983","journal-title":"Fertil Steril"},{"key":"R14-7-20211004","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM198903023200904","article-title":"Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome","volume":"320","author":"Barnes","year":"1989","journal-title":"N Engl J Med"},{"key":"R15-7-20211004","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0002-9378(84)90720-8","article-title":"The control of bioactive luteinizing hormone secretion in women with polycystic ovary syndrome","volume":"148","author":"Lobo","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"R16-7-20211004","first-page":"E902","article-title":"Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome","volume":"286","author":"McCartney","year":"2004","journal-title":"Am J Physiol"},{"key":"R17-7-20211004","first-page":"1686","article-title":"Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism","volume":"79","author":"Rosenfield","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-7-20211004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2265.1997.2321049.x","article-title":"Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome","volume":"47","author":"Gilling-Smith","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R19-7-20211004","first-page":"2317","article-title":"Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis","volume":"83","author":"Azziz","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-7-20211004","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1210\/jcem-49-6-892","article-title":"Adrenal function in normal women and women with the polycystic ovary syndrome","volume":"49","author":"Lachelin","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-7-20211004","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2337\/diab.38.9.1165","article-title":"Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome","volume":"38","author":"Dunaif","year":"1989","journal-title":"Diabetes"},{"key":"R22-7-20211004","first-page":"E392","article-title":"Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS)","volume":"281","author":"Dunaif","year":"2001","journal-title":"Am J Physiol"},{"key":"R23-7-20211004","first-page":"2854","article-title":"Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features","volume":"81","author":"Morales","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-7-20211004","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/endo-108-4-1441","article-title":"Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells","volume":"108","author":"Adashi","year":"1981","journal-title":"Endocrinology"},{"key":"R25-7-20211004","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1210\/jcem-62-5-904","article-title":"Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism","volume":"62","author":"Barbieri","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-7-20211004","first-page":"2001","article-title":"Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system","volume":"83","author":"Nestler","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-7-20211004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1210\/jcem-72-1-83","article-title":"A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome","volume":"72","author":"Nestler","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-7-20211004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0303-7207(98)00177-4","article-title":"Role of cytochrome P450c17 in polycystic ovary syndrome","volume":"145","author":"Qin","year":"1998","journal-title":"Molecular and cellular endocrinology"},{"key":"R29-7-20211004","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.fertnstert.2004.01.041","article-title":"Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome","volume":"82","author":"Carmina","year":"2004","journal-title":"Fertil Steril"},{"key":"R30-7-20211004","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1210\/jc.2004-0410","article-title":"Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients","volume":"90","author":"Ciampelli","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-7-20211004","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1210\/jc.2003-031205","article-title":"Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome","volume":"89","author":"Diamanti-Kandarakis","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-7-20211004","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/humrep\/dei455","article-title":"Follow-up study of two sisters with type A syndrome of severe insulin resistance gives a new insight into PCOS pathogenesis in relation to puberty and pregnancy outcome: a case report","volume":"21","author":"Vambergue","year":"2006","journal-title":"Hum Reprod"},{"key":"R33-7-20211004","doi-asserted-by":"crossref","first-page":"851","DOI":"10.7326\/0003-4819-97-6-851","article-title":"Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor","volume":"97","author":"Taylor","year":"1982","journal-title":"Ann Intern Med"},{"key":"R34-7-20211004","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1210\/jc.2006-0108","article-title":"Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus","volume":"91","author":"Codner","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-7-20211004","first-page":"4182","article-title":"High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus","volume":"85","author":"Escobar-Morreale","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-7-20211004","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2265.1995.tb02686.x","article-title":"The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: its association with hyperinsulinism","volume":"42","author":"Lee","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R37-7-20211004","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1515\/JPEM.2005.18.5.423","article-title":"Endocrine and metabolic changes in epileptic patients receiving valproic acid","volume":"18","author":"Verrotti","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R38-7-20211004","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1210\/jcem-68-6-1027","article-title":"Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome","volume":"68","author":"Nestler","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-7-20211004","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1210\/jc.2004-2490","article-title":"Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome","volume":"90","author":"Gambineri","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R40-7-20211004","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1093\/humrep\/14.12.2951","article-title":"Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia","volume":"14","author":"Ciotta","year":"1999","journal-title":"Hum Reprod"},{"key":"R41-7-20211004","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/01443619768614","article-title":"The effects of somatostatin in the polycystic ovary syndrome","volume":"17","author":"Rosina","year":"1997","journal-title":"J Obstet Gynaecol"},{"key":"R42-7-20211004","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0897.1994.tb00854.x","article-title":"Octreotide effect on ovarian morphology in insulin-resistant PCOS patients following six-month decapeptyl treatment","volume":"31","author":"Goni","year":"1994","journal-title":"Am J Reprod Immunol"},{"key":"R43-7-20211004","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2265.1996.00863.x","article-title":"Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome","volume":"45","author":"Sampson","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R44-7-20211004","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.metabol.2006.04.002","article-title":"Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea","volume":"55","author":"Vgontzas","year":"2006","journal-title":"Metabolism"},{"key":"R45-7-20211004","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1210\/jc.2003-031096","article-title":"Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease","volume":"89","author":"Boulman","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R46-7-20211004","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/jcem.87.7.8634","article-title":"A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome","volume":"87","author":"Kelly","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R47-7-20211004","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/jcem.86.6.7580","article-title":"Low grade chronic inflammation in women with polycystic ovarian syndrome","volume":"86","author":"Kelly","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R48-7-20211004","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0009-9120(01)00245-4","article-title":"Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease","volume":"34","author":"Sabuncu","year":"2001","journal-title":"Clin Biochem"},{"key":"R49-7-20211004","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1210\/jc.2003-031365","article-title":"Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity","volume":"89","author":"Escobar-Morreale","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R50-7-20211004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2004-0628","article-title":"The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome","volume":"90","author":"Orio","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R51-7-20211004","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1507\/endocrj.51.601","article-title":"Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia","volume":"51","author":"Bayraktar","year":"2004","journal-title":"Endocr J"},{"key":"R52-7-20211004","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/09513590400027265","article-title":"Levels of lipoprotein and homocysteine in nonobese and obese patients with polycystic ovary syndrome","volume":"20","author":"Yilmaz","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"R53-7-20211004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000058367","article-title":"The plasma homocysteine levels are increased in polycystic ovary syndrome","volume":"53","author":"Loverro","year":"2002","journal-title":"Gynecologic and obstetric investigation"},{"key":"R54-7-20211004","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0015-0282(01)01937-9","article-title":"Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome","volume":"76","author":"Yarali","year":"2001","journal-title":"Fertil Steril"},{"key":"R55-7-20211004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.22.1.141","article-title":"Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome","volume":"22","author":"Ehrmann","year":"1999","journal-title":"Diabetes Care"},{"key":"R56-7-20211004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11892-006-0056-1","article-title":"Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up","volume":"6","author":"Boudreaux","year":"2006","journal-title":"Curr Diab Rep"},{"key":"R57-7-20211004","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/humrep\/16.9.1995","article-title":"Relative risk of conversion from normoglycaemia to impaired glucose tolerance or noninsulin dependent diabetes mellitus in polycystic ovarian syndrome","volume":"16","author":"Norman","year":"2001","journal-title":"Hum Reprod"},{"key":"R58-7-20211004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0015-0282(16)54892-4","article-title":"Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones","volume":"57","author":"Dahlgren","year":"1992","journal-title":"Fertil Steril"},{"key":"R59-7-20211004","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/jc.2005-2430","article-title":"Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome","volume":"91","author":"Lo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R60-7-20211004","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1389-9457(02)00033-3","article-title":"The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome","volume":"3","author":"Gopal","year":"2002","journal-title":"Sleep Med"},{"key":"R61-7-20211004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1210\/jc.2005-1084","article-title":"Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome","volume":"91","author":"Tasali","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R62-7-20211004","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1530\/eje.1.01868","article-title":"Evidence for altered adipocyte function in polycystic ovary syndrome","volume":"152","author":"Carmina","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"R63-7-20211004","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/jcem.87.2.8199","article-title":"Altered vascular function in young women with polycystic ovary syndrome","volume":"87","author":"Kelly","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R64-7-20211004","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2265.2006.02645.x","article-title":"Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors","volume":"65","author":"Sorensen","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R65-7-20211004","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1210\/jc.2003-031867","article-title":"Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome","volume":"89","author":"Orio","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R66-7-20211004","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1210\/jc.2005-0151","article-title":"Predictors of endothelial dysfunction in young women with polycystic ovary syndrome","volume":"90","author":"Kravariti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R67-7-20211004","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1210\/jc.2003-030334","article-title":"Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome","volume":"88","author":"Christian","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R68-7-20211004","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1210\/jc.2006-0216","article-title":"Cardiopulmonary impairment in young women with polycystic ovary syndrome","volume":"91","author":"Orio","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R69-7-20211004","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0002-9378(96)70665-8","article-title":"Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case\u2013control study","volume":"174","author":"Guzick","year":"1996","journal-title":"American J Obstet Gynecol"},{"key":"R70-7-20211004","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/1464727002000198781","article-title":"Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study","volume":"3","author":"Wild","year":"2000","journal-title":"Hum Fertil (Camb)"},{"key":"R71-7-20211004","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01000.x","article-title":"Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study","volume":"52","author":"Wild","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R72-7-20211004","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/jc.2005-2774","article-title":"Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome","volume":"91","author":"Setji","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R73-7-20211004","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dml036","article-title":"A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome","volume":"12","author":"Boomsma","year":"2006","journal-title":"Human reproduction update"},{"key":"R74-7-20211004","first-page":"15","article-title":"Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome","volume":"60","author":"Raj","year":"1982","journal-title":"Obstet Gynecol"},{"key":"R75-7-20211004","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.fertnstert.2005.07.1306","article-title":"Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome","volume":"85","author":"Mastorakos","year":"2006","journal-title":"Fertil Steril"},{"key":"R76-7-20211004","first-page":"3161","article-title":"Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study","volume":"85","author":"Morin-Papunen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R77-7-20211004","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0015-0282(02)02993-X","article-title":"Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives","volume":"77","author":"Mastorakos","year":"2002","journal-title":"Fertil Steril"},{"key":"R78-7-20211004","first-page":"3327","article-title":"Metabolic effects of oral contraceptives in women with polycystic ovary syndrome","volume":"80","author":"Korytkowski","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R79-7-20211004","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2002-021528","article-title":"A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills","volume":"88","author":"Diamanti-Kandarakis","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"R80-7-20211004","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.fertnstert.2006.04.014","article-title":"Use of antiandrogens as therapy for women with polycystic ovary syndrome","volume":"86","author":"Moghetti","year":"2006","journal-title":"Fertil Steril"},{"key":"R81-7-20211004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0889-8529(05)70077-3","article-title":"Antiandrogen treatment of polycystic ovary syndrome","volume":"28","author":"Rittmaster","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R82-7-20211004","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1210\/jc.2005-1490","article-title":"The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery","volume":"90","author":"Escobar-Morreale","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R83-7-20211004","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1210\/jc.2004-0176","article-title":"Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome","volume":"90","author":"Jayagopal","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R84-7-20211004","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0015-0282(03)02162-9","article-title":"Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome","volume":"80","author":"Sabuncu","year":"2003","journal-title":"Fertil Steril"},{"key":"R85-7-20211004","first-page":"207","article-title":"Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women","volume":"105","author":"Lazurova","year":"2004","journal-title":"Bratisl Lek Listy"},{"key":"R86-7-20211004","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/humrep\/16.10.2066","article-title":"Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance","volume":"16","author":"Ciotta","year":"2001","journal-title":"Hum Reprod"},{"key":"R87-7-20211004","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/humrep\/dei104","article-title":"Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study","volume":"20","author":"Penna","year":"2005","journal-title":"Hum Reprod"},{"key":"R88-7-20211004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1592\/phco.25.2.244.56943","article-title":"Thiazolidinediones for treatment of polycystic ovary syndrome","volume":"25","author":"Stout","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"Suppl 3","key":"R89-7-20211004","first-page":"3","article-title":"Pharmacology of alpha-glucosidase inhibition","volume":"24","author":"Bischoff","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"R90-7-20211004","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1464-5491.1999.00023.x","article-title":"Thiazolidinediones: a new class of antidiabetic drugs","volume":"16","author":"Day","year":"1999","journal-title":"Diabet Med"},{"key":"R91-7-20211004","first-page":"233","article-title":"Metformin: a review of its pharmacological properties and therapeutic use","volume":"5","author":"Hermann","year":"1979","journal-title":"Diabete Metab"},{"key":"R92-7-20211004","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1210\/jc.2004-0463","article-title":"Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment","volume":"89","author":"Ibanez","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R93-7-20211004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpeds.2003.08.015","article-title":"Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome","volume":"144","author":"Ibanez","year":"2004","journal-title":"J Pediatr"},{"key":"R94-7-20211004","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1210\/jc.2005-0965","article-title":"Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study","volume":"90","author":"Orio","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R95-7-20211004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2265.2006.02551.x","article-title":"Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance","volume":"65","author":"Topcu","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R96-7-20211004","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/humrep\/del003","article-title":"Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin","volume":"21","author":"Diamanti-Kandarakis","year":"2006","journal-title":"Hum Reprod"},{"key":"R97-7-20211004","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1515\/JPEM.2006.19.6.831","article-title":"Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome","volume":"19","author":"Glueck","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R98-7-20211004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpedi.160.3.241","article-title":"Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome","volume":"160","author":"Bridger","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R99-7-20211004","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ajog.2005.11.009","article-title":"Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin","volume":"194","author":"Banaszewska","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R100-7-20211004","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jcem.87.2.8261","article-title":"Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial","volume":"87","author":"Fleming","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R101-7-20211004","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","article-title":"Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy","volume":"43","author":"Velazquez","year":"1994","journal-title":"Metabolism"},{"key":"R102-7-20211004","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"R103-7-20211004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.resp.2005.02.011","article-title":"Effect of high-fat diet and metformin treatment on ventilation and sleep apnea in nonobese rats","volume":"150","author":"Ramadan","year":"2006","journal-title":"Respir Physiol Neurobiol"},{"key":"R104-7-20211004","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0015-0282(02)04925-7","article-title":"Metformin has direct effects on human ovarian steroidogenesis","volume":"79","author":"Mansfield","year":"2003","journal-title":"Fertil Steril"},{"key":"R105-7-20211004","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0015-0282(01)01975-6","article-title":"Metformin directly inhibits androgen production in human thecal cells","volume":"76","author":"Attia","year":"2001","journal-title":"Fertil Steril"},{"key":"R106-7-20211004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/eje.0.1470217","article-title":"The effect of metformin on hirsutism in polycystic ovary syndrome","volume":"147","author":"Kelly","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"R107-7-20211004","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1210\/jc.2003-030424","article-title":"Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome","volume":"88","author":"Harborne","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R108-7-20211004","first-page":"139","article-title":"Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation","volume":"85","author":"Moghetti","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R109-7-20211004","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.fertnstert.2004.05.098","article-title":"Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment","volume":"83","author":"Fleming","year":"2005","journal-title":"Fertil Steril"},{"key":"R110-7-20211004","first-page":"4075","article-title":"Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens","volume":"82","author":"Nestler","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R111-7-20211004","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJM199608293350902","article-title":"Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome","volume":"335","author":"Nestler","year":"1996","journal-title":"N Engl J Med"},{"key":"R112-7-20211004","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jcem.87.4.8398","article-title":"Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia\/insulin resistance","volume":"87","author":"Arslanian","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R113-7-20211004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/humrep\/15.1.21","article-title":"Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome","volume":"15","author":"la Marca","year":"2000","journal-title":"Hum Reprod"},{"key":"R114-7-20211004","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/humrep\/16.12.2546","article-title":"Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin","volume":"16","author":"Koivunen","year":"2001","journal-title":"Hum Reprod"},{"key":"R115-7-20211004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.0.1380269","article-title":"Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome","volume":"138","author":"Diamanti-Kandarakis","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"R116-7-20211004","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jcem.85.4.6560","article-title":"Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome","volume":"85","author":"De Leo","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R117-7-20211004","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1472-6483(10)61079-6","article-title":"Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance","volume":"12","author":"Ulloa-Aguirre","year":"2006","journal-title":"Reprod Biomed Online"},{"key":"R118-7-20211004","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.fertnstert.2003.05.020","article-title":"Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome","volume":"81","author":"Genazzani","year":"2004","journal-title":"Fertil Steril"},{"key":"R119-7-20211004","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jc.2005-1994","article-title":"Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial","volume":"91","author":"Eisenhardt","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R120-7-20211004","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0015-0282(98)00011-9","article-title":"Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome","volume":"69","author":"Morin-Papunen","year":"1998","journal-title":"Fertil Steril"},{"key":"R121-7-20211004","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/humrep\/deh850","article-title":"Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome","volume":"20","author":"Piltonen","year":"2005","journal-title":"Hum Reprod"},{"key":"R122-7-20211004","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.fertnstert.2005.12.036","article-title":"Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome","volume":"86","author":"Essah","year":"2006","journal-title":"Fertil Steril"},{"key":"R123-7-20211004","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1056\/NEJM199806253382603","article-title":"Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome","volume":"338","author":"Nestler","year":"1998","journal-title":"N Engl J Med"},{"key":"R124-7-20211004","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/jc.2003-030975","article-title":"Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy","volume":"89","author":"Jakubowicz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R125-7-20211004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/humrep\/dei351","article-title":"Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome","volume":"21","author":"Palomba","year":"2006","journal-title":"Hum Reprod"},{"key":"R126-7-20211004","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1210\/jc.2005-0110","article-title":"Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome","volume":"90","author":"Palomba","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R127-7-20211004","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/bmj.38867.631551.55","article-title":"Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial","volume":"332","author":"Moll","year":"2006","journal-title":"BMJ"},{"key":"R128-7-20211004","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0015-0282(01)02941-7","article-title":"Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome","volume":"77","author":"Kocak","year":"2002","journal-title":"Fertil Steril"},{"key":"R129-7-20211004","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0015-0282(00)01675-7","article-title":"Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone","volume":"75","author":"Vandermolen","year":"2001","journal-title":"Fertil Steril"},{"key":"R130-7-20211004","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/humrep\/16.8.1625","article-title":"Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial","volume":"16","author":"Ng","year":"2001","journal-title":"Hum Reprod"},{"key":"R131-7-20211004","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1365-2125.2002.01575.x","article-title":"Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice","volume":"53","author":"Sturrock","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R132-7-20211004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0015-0282(00)01766-0","article-title":"Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors","volume":"75","author":"Stadtmauer","year":"2001","journal-title":"Fertil Steril"},{"key":"R133-7-20211004","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0015-0282(99)00208-3","article-title":"Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome","volume":"72","author":"De Leo","year":"1999","journal-title":"Fertil Steril"},{"key":"R134-7-20211004","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/humrep\/del025","article-title":"The use of metformin for women with PCOS undergoing IVF treatment","volume":"21","author":"Tang","year":"2006","journal-title":"Hum Reprod"},{"key":"R135-7-20211004","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.fertnstert.2005.03.043","article-title":"Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial","volume":"84","author":"Onalan","year":"2005","journal-title":"Fertil Steril"},{"key":"R136-7-20211004","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/humrep\/deh263","article-title":"Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy","volume":"19","author":"Glueck","year":"2004","journal-title":"Hum Reprod"},{"key":"R137-7-20211004","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jpeds.2006.01.011","article-title":"Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome","volume":"148","author":"Glueck","year":"2006","journal-title":"J Pediatr"},{"key":"R138-7-20211004","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14767050600682370","article-title":"Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy","volume":"19","author":"Kovo","year":"2006","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R139-7-20211004","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0015-0282(01)03202-2","article-title":"Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome","volume":"77","author":"Glueck","year":"2002","journal-title":"Fertil Steril"},{"key":"R140-7-20211004","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/humrep\/17.11.2858","article-title":"Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin","volume":"17","author":"Glueck","year":"2002","journal-title":"Hum Reprod"},{"key":"R141-7-20211004","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/jcem.87.2.8207","article-title":"Effects of metformin on early pregnancy loss in the polycystic ovary syndrome","volume":"87","author":"Jakubowicz","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R142-7-20211004","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/humrep\/dei311","article-title":"Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study","volume":"21","author":"Tang","year":"2006","journal-title":"Hum Reprod"},{"key":"R143-7-20211004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.2004.01973.x","article-title":"Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome","volume":"60","author":"Gambineri","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R144-7-20211004","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1210\/jcem.85.8.6738","article-title":"Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome","volume":"85","author":"Pasquali","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R145-7-20211004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/humrep\/deh580","article-title":"Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome","volume":"20","author":"Sonmez","year":"2005","journal-title":"Hum Reprod"},{"key":"R146-7-20211004","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/BF03345339","article-title":"The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome","volume":"28","author":"Yilmaz","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"R147-7-20211004","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1093\/humrep\/dei258","article-title":"The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome","volume":"20","author":"Yilmaz","year":"2005","journal-title":"Hum Reprod"},{"key":"R148-7-20211004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/09513590500231627","article-title":"The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome","volume":"21","author":"Yilmaz","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"R149-7-20211004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejogrb.2005.11.019","article-title":"Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome","volume":"126","author":"Mitkov","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R150-7-20211004","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.fertnstert.2004.02.127","article-title":"Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity","volume":"82","author":"Baillargeon","year":"2004","journal-title":"Fertil Steril"},{"key":"R151-7-20211004","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.fertnstert.2005.07.1312","article-title":"A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome","volume":"85","author":"Rouzi","year":"2006","journal-title":"Fertil Steril"},{"key":"R152-7-20211004","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2004-1965","article-title":"Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome","volume":"90","author":"Ortega-Gonzalez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R153-7-20211004","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/humrep\/deg343","article-title":"Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin","volume":"18","author":"Glueck","year":"2003","journal-title":"Hum Reprod"},{"key":"R154-7-20211004","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/09513590400004736","article-title":"Metformin versus flutamide in the treatment of metabolic consequences of nonobese young women with polycystic ovary syndrome: a randomized prospective study","volume":"19","author":"Sahin","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"R155-7-20211004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.1.01840","article-title":"Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and nonobese women with polycystic ovary syndrome","volume":"152","author":"Rautio","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"R156-7-20211004","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/JPEM.2005.18.8.761","article-title":"Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome","volume":"18","author":"Allen","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R157-7-20211004","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.fertnstert.2003.06.022","article-title":"Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome","volume":"81","author":"Vanky","year":"2004","journal-title":"Fertil Steril"},{"key":"R158-7-20211004","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/humrep\/17.7.1729","article-title":"Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in nonobese women with polycystic ovarian syndrome: a randomized controlled study","volume":"17","author":"Elter","year":"2002","journal-title":"Hum Reprod"},{"key":"R159-7-20211004","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/humrep\/deh588","article-title":"The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients","volume":"20","author":"Cibula","year":"2005","journal-title":"Hum Reprod"},{"key":"R160-7-20211004","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/humupd\/dmi054","article-title":"Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women","volume":"12","author":"Ibanez","year":"2006","journal-title":"Human Reprod Update"},{"key":"R161-7-20211004","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2005-2250","article-title":"Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study","volume":"91","author":"Gambineri","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R162-7-20211004","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/humrep\/dei329","article-title":"Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil\/lymphocyte ratio","volume":"21","author":"Ibanez","year":"2006","journal-title":"Hum Reprod"},{"key":"R163-7-20211004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jc.2004-1405","article-title":"Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy","volume":"90","author":"Ibanez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R164-7-20211004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/humrep\/deg056","article-title":"Low-dose combination of flutamide, metformin and an oral contraceptive for nonobese, young women with polycystic ovary syndrome","volume":"18","author":"Ibanez","year":"2003","journal-title":"Hum Reprod"},{"key":"R165-7-20211004","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1093\/humrep\/dei072","article-title":"High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception","volume":"20","author":"Ibanez","year":"2005","journal-title":"Hum Reprod"},{"key":"R166-7-20211004","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF00275941","article-title":"Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy","volume":"24","author":"Adams","year":"1983","journal-title":"Diabetologia"},{"key":"R167-7-20211004","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/00365527109179948","article-title":"Effects of a biguanide (Metformin) on vitamin B12 and folic acid absorption and intestinal enzyme activities","volume":"6","author":"Berchtold","year":"1971","journal-title":"Scand J Gastroenterol"},{"key":"R168-7-20211004","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2337\/diacare.23.9.1227","article-title":"Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin","volume":"23","author":"Bauman","year":"2000","journal-title":"Diabetes Care"},{"key":"R169-7-20211004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-2002-23489","article-title":"Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome","volume":"110","author":"Vrbikova","year":"2002","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R170-7-20211004","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/humrep\/deh825","article-title":"Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial","volume":"20","author":"Kilicdag","year":"2005","journal-title":"Hum Reprod"},{"key":"R171-7-20211004","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2796.1998.00361.x","article-title":"Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment","volume":"244","author":"Aarsand","year":"1998","journal-title":"J Intern Med"},{"key":"R172-7-20211004","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1210\/jcem.86.3.7352-9","article-title":"Metformin and the polycystic ovary syndrome","volume":"86","author":"Nestler","year":"2001","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01266029-200704000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:50:48Z","timestamp":1786042248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01266029-200704000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":171,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0b013e328089f0ea","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}